Ironwood Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Alexander Denner, Ph.D.

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Alexander Denner, Ph.D.”): 104,323,731 for, 5,313,973 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected eight director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based…”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 42,124,002 for, 57,115 withheld, 184,355 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Catherine Moukheibir

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Catherine Moukheibir”): 106,410,985 for, 3,226,719 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected eight director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based…”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 42,144,471 for, 36,653 withheld, 184,348 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Jay Shepard

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jay Shepard”): 107,209,046 for, 2,428,658 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected eight director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based…”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 42,144,474 for, 36,653 withheld, 184,345 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Jon Duane

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jon Duane”): 105,956,515 for, 3,681,189 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected eight director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based…”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 42,130,698 for, 50,426 withheld, 184,348 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Julie McHugh

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Julie McHugh”): 104,403,033 for, 5,234,671 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected eight director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based…”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 42,123,823 for, 57,295 withheld, 184,354 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Mark Currie, Ph.D.

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Mark Currie, Ph.D.”): 107,222,711 for, 2,414,993 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected eight director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based…”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 42,144,474 for, 36,653 withheld, 184,345 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Marla Kessler

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Marla Kessler”): 107,142,336 for, 2,495,368 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected eight director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based…”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 42,144,474 for, 36,653 withheld, 184,345 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Thomas McCourt

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Thomas McCourt”): 107,152,086 for, 2,485,618 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected eight director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based…”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 42,144,474 for, 36,653 withheld, 184,345 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: APPROVAL OF AN AMENDMENT TO IRONWOOD PHARMACEUTICALS, INC. AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE THEREUNDER BY 10,000,000 SHARES.

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“3. The Plan Amendment, based on the following votes”): 104,066,785 for, 5,404,112 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved the Plan Amendment, based on the following votes:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Ironwood Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (2 managers, 105,305 for).

The 64 asset managers below reported 42,033,763 for, 209,858 against, 16,546 abstained.

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

Description as filed by funds: Approval, by non-binding advisory vote, of the compensation paid to the named executive officers.

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“2. On a non-binding advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement for the Annual Meeting, based on the following votes”): 104,461,936 for, 4,958,394 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement for the Annual Meeting, based on the following votes:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 66 managers: 42,229,287 for, 119,639 against, 16,546 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 149 managers: 65,554,630 for, 1,146,123 against, 247 abstained, 2,344 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: RATIFICATION OF THE SELECTION OF KPMG LLP AS IRONWOOD PHARMACEUTICALS, INC.'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR 2026.

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“4. The selection of KPMG LLP as the Company's independent registered public accounting firm for 2026, based on the following votes”): 121,957,895 for, 2,783,154 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for 2026, based on the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 41,981,583 for, 367,343 against, 16,546 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.